IntelGenx Technologies Corp. IGXT
0.17 0.00 (+0.00%)
At closeMay 27, 2025, 4:00 PM EDT
0.1593 Day range 0.17
52-week range unavailable
- Market cap
- 29.69M
- Volume
- 37.23K
- Open
- 0.1593
- Previous close
- 0.17
- Day's range
- 0.1593 – 0.17
- Earnings date
- Dec 26, 2024
No chart data for this range yet.
Next earnings
Dec 26, 2024
Expected Dec 26, 2024. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 26, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Sep 30, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.02 | — | — |
| Mar 21, 2024 | Dec 1, 2023 | 0.00 | -0.02 | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | -0.01 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -0.02 | — | — |
News
IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG 
IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process 
IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA' Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease 
IntelGenx Announces Initiation of the Sale and Investment Solicitation Process 
IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process 
IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives 
IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives 
IntelGenx Announces Voting Results on Election of Directors 
IntelGenx Announces First Parkinson's Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK' Clinical Trial 
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
Your note
Sign in to keep a note on IGXT — it syncs with the Stock Master app.